MDT - Mitotic spindle poisons Flashcards

1
Q

What is a spindle poison?

A

a spindle toxin, is a poison that disrupts cell division by affecting the protein threads that connect the centromere regions of chromosomes, known as spindles. Spindle poisons effectively cease the production of new cells by interrupting the mitosis phase of cell division at the spindle assembly checkpoint (SAC).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the mitotic spindle?

A

The mitotic spindle is composed of microtubules (polymerized tubulin) that aid, along with regulatory proteins; each other in the activity of appropriately segregating replicated chromosomes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the two specific families of antimitotic agents?

A

Vinca alkaloids

Taxanes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do the vinca alkaloids work?

A

Inhibit the polymerisation of tubulin into microtubules, resulting in G2/M arrest in the cell cycle and eventually cell death.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do the taxanes work?

A

They stabilise microtubules against depolymerisation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is vinblastine?

A

A vinca alkaloid.

It binds to the + end of the microtubules, capping it and preventing new tubule dimers from adding on.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

_____ ______ bind strongly to individual tubulin dimers, causing conformational change and preventing binding to microtubules.

A

Vinca alkaloids bind strongly to individual tubulin dimers, causing conformational change and preventing binding to microtubules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Individual complexes of _____ _______ and tubulin dimers condense into paracrystalline aggregates.

A

Individual complexes of vinca alkaloid and tubulin dimers condense into paracrystalline aggregates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does Le Chateliers Principle apply to the action of vinca alkaloids such as _________?

A

Vinblastine.

Microtubules shrink.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How do Taxols work?

A

Taxols bind to taxol-binding sites on the inside surface of the microtubule, preventing disassembly.

Inappropriate microtubules remain.

Concentration of free tubulin dimers decreases as more and more microtubules are made which cannot subsequently be broken down.

The low concentrations of free tubulin dimers means that new microtubules cannot be assembled.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are two examples of taxols?

A

Docetaxel.

Paclitaxel.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do Colchicine-like drugs work?

A

Bind to colchicine binding sites on the B-tubulin subunits, disfavouring assembly of protofilaments.

ALSO

Colchicine bound at colchicine binding sites on B-tubulin in microtubules disfavours disassembly of inappropriate microtubules.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do vinca alkaloids prevent tubulin dimers from binding to microtubules?

A

Vinblastine binds to + end of microtubule, capping it and preventing new tubulin dimers from adding.

Vinca alkaloids bind strongly to individual tubulin dimers, causing conformational change and preventing binding to microtubules.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Docetaxel and Paclitaxel are examples of

A

Taxols

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drug class that causes innappropriate microtubules to remain and concentration of free tubulin dimers to decrease.

A

Taxols

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Combretastatin A-4 is an example of what?

A

Colchicine like drug, which is in clinical trial

17
Q

Is colchicine approved for the treatment of cancer?

A

No - only for gout.

18
Q

Newer targets in cancer chemotherapy focus on

A
  1. Potentiation of DNA-damaging therapies.
  2. Exploitation of the abnormal physiology of solid tumours.
  3. Inhibition of angiogenesis.
  4. Interference with signalling, especially cell cycle control.
  5. Interference with management of DNA in the tumour cell.